Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
Journal
Breast Cancer Research and Treatment
Journal Volume
189
Journal Issue
3
Pages
665-676
Date Issued
2021
Author(s)
Dai M.S.
Feng Y.H.
Chen S.W.
Masuda N.
Yau T.
Chen S.T.
Yap Y.S.
Ang P.C.S.
Chu S.C.
Kwong A.
Lee K.S.
Ow S.
Kim S.B.
Lin J.
Chung H.C.
Ngan R.
Kok V.C.
Rau K.M.
Sangai T.
Ng T.Y.
Tseng L.M.
Bryce R.
Bebchuk J.
Chen M.C.
Hou M.F.
SDGs
Publisher
Springer
Type
journal article